Livalo, developed by Kowa, is a cholesterol-lowering agent and Olmetec, developed by Daiichi, is an antihypertensive agent.
Both the companies have been jointly marketing the drugs in the region since their launch but subsequent to the review of sales strategy and discussions a decision to close the agreement is taken.
From 1 July 2013, Kowa will solely conduct the promotion and marketing activities of Livalo tablets and Daiichi Sankyo will solely conduct the Olmetec promotion and marketing activites.